A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: A California Cancer Consortium trial

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 741-748

  Li, Tianhong ^a   Christensen, Scott D ^a   Frankel, Paul H ^b   Margolin, Kim A ^b,d   Agarwala, Sanjiv S ^c,e   Luu, Thehang ^b   MacK, Philip C ^a   Lara Jr , Primo N ^a   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d Seattle Cancer Center Alliance   (United States)

^e St Luke's Cancer Center   (United States)

Author keywords

7 hydroxystaurosporine; Cell cycle inhibitor; Metastatic melanoma; Phase II; Targeted therapy; UCN 01

Indexed keywords

7 HYDROXYSTAUROSPORINE; KI 67 ANTIGEN; PROTEIN P27; RETINOBLASTOMA PROTEIN; 7-HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; STAUROSPORINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CELL CYCLE REGULATION; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DESQUAMATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERMAGNESEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY DISEASE; LYMPHOCYTOPENIA; MALE; METABOLIC DISORDER; METASTATIC MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISEASE; SOMNOLENCE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; CELL CYCLE; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MELANOMA; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SKIN TUMOR; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CALIFORNIA; CELL CYCLE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SKIN NEOPLASMS; STAUROSPORINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861547375     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9562-8     Document Type: Article

References (33)

1. Jemal A et al (2010) Cancer Statistics, 2010. CA Cancer J Clin
2. Barth A, Wanek LA, Morton DL (1995) Prognostic factors in 1, 521 melanoma patients with distant metastases. J Am Coll Surg 181(3):193-201
3. Tawbi HA, Buch SC (2010) Chemotherapy resistance abrogation in metastatic melanoma. Clin Adv Hematol Oncol 8(4):259-266
4. Mouawad R et al (2010) Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol 74(1):27-39
5. Yang AS, Chapman PB (2009) The history and future of chemotherapy for melanoma. Hematol Oncol Clin North Am 23 (3):583-597, x
6. Middleton MR et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18 (1):158-166
7. Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723
8. Sauroja I et al (2000) Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosom Cancer 28(4):404-414
9. High WA, Robinson WA (2007) Genetic mutations involved in melanoma: a summary of our current understanding. Adv Dermatol 23:61-79
10. Palmieri G et al (2000) Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. The Melanoma Cooperative Group. Br J Cancer 83(12):1707-1714
11. Vuhahula E, Straume O, Akslen LA (2000) Frequent loss of p16 protein expression and high proliferative activity (Ki-67) in malignant melanoma from black Africans. Anticancer Res 20(6C):4857-4862
12. Takahashi I et al (1987) UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J Antibiot (Tokyo) 40(12):1782-1784
13. Takahashi I et al (1990) Potent selective inhibition of 7-O-methyl UCN-01 against protein kinase C. J Pharmacol Exp Ther 255 (3):1218-1221
14. Akiyama T et al (1999) G1-checkpoint function including a cyclindependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation. Jpn J Cancer Res 90(12):1364-1372
15. Akiyama T et al (1997) G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 57(8):1495-1501
16. Abe S et al (2001) UCN-01 (7-hydoxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery. Jpn J Cancer Res 92(5):537-545
17. Fuse E et al (2005) Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol 45 (4):394-403
18. Kurata N et al (1999) Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01. Cancer Chemother Pharmacol 44(1):12-18
19. Dees EC et al (2005) A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clin Cancer Res 11(2 Pt 1):664-671
20. Sausville EA et al (2001) Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19(8):2319-2333
21. Lara PN Jr et al (2005) The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res 11(12):4444-4450
22. Hotte SJ et al (2006) Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann Oncol 17 (2):334-340
23. Jimeno A et al (2008) Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother Pharmacol 61(3):423-433
24. Welch S et al (2007) UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecol Oncol 106(2):305-310
25. Fracasso PM et al (2010) A phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol
26. Kummar S et al (2010) A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. Cancer Chemother Pharmacol 65(2):383-389
27. Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
28. Rodolfo M, Pierotti MA, Parmiani G (2005) A merging duo in melanoma formation. J Invest Dermatol 125(6):xii-xiii
29. Lazar-Molnar E et al (2000) Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12(6):547-554
30. Porter GA et al (2001) Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol 8(2):116-122
31. Sausville EA (2003) Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies. Curr Med Chem Anticancer Agents 3(1):47-56
32. Senderowicz AM (2005) Inhibitors of cyclin-dependent kinase modulators for cancer therapy. Prog Drug Res 63:183-206
33. Flaherty KT, McArthur G (2010) BRAF, a target in melanoma: implications for solid tumor drug development. Cancer